-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

AI in Hematology: Where Do You Stand in 2023?

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
artificial intelligence (AI), Technology and Procedures
Monday, December 11, 2023: 10:30 AM-12:00 PM
Room 11 (San Diego Convention Center)
Torsten Haferlach, MD, PhD, MLL Munich Leukemia Laboratory
Haferlach: MLL Munich Leukemia Laboratory: Current Employment, Other: Equity Ownership.
Few new tools are attributed with as much potential, disruptive energy, and opportunities for use or abuse as the recent developments in the field of artificial intelligence (AI). These are challenges we must confront in both our personal and professional lives. Particularly in the field of medicine, where our obligation to research and act for the well-being of our patients is paramount, the potential use of AI is also of fundamental importance. The session compiled here will therefore shed light on various aspects from experts. This includes existing possibilities, such as the use of AI in radiological diagnostics. We will discuss its potential to enhance drug discovery, and safety assessments, and develop new medications. Additionally, we want to explore the extent to which AI is already being used or can be used in the near future in the Hematology Clinic, for diagnostics and therapy decisions. The entire discussion will be framed within the context of all aforementioned topics, when addressing urgent ethical issues, to provide knowledge for critical evaluation of how to apply AI in medicine today.

Weida Tong, Ph.D.

Division of Bioinformatics and Biostatistics, National Center for Toxicological Research (USFDA), Jefferson, AR

Yates Coley, PhD

Kaiser Permanente Washington Health Research Institute, Seattle

Torsten Haferlach, MD, PhD

MLL Munich Leukemia Laboratory, Munich, Germany